



RECEIVED  
JUN 27 2003  
TC 1700

Response/54(3)/#8  
J 7.2.03  
RECEIVED  
JUN 30 2003  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : Barbera-Guillem Examiner : A. Holleran  
Application No. : 09/835,759 Group Art : 1642  
Filing Date : April 16, 2001  
Title : VACCINE AND IMMUNOTHERAPY FOR SOLID  
NONLYMPHOID TUMOR AND RELATED IMMUNE  
DYSREGULATION  
Docket No. : B-63 (old)  
26983-98 (new)

Mail Stop Non-Fee Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO SECOND RESTRICTION REQUIREMENT**

Dear Examiner:

In response to the second Restriction Requirement dated December 18, 2002, Applicant provisionally elects, with traverse, the species comprising a mAb having specificity for a determinant selected from the group consisting of CD19, CD20, CD21, CD22 (also known as LL2), CDIM, and Lym-1.

The three-month period for replying to this Office Action expired on March 18, 2003. Accordingly, Applicant submits herewith a petition for a three-month extension of time under 37